STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

已收盘 11-15 16:00:00 EST

34.17

-3.52

-9.34%

盘后34.17

+0.000.00%

19:30 EST

最高37.76	最低33.92	成交量107.78万
今开37.75	昨收37.69	日振幅10.19%
总市值19.54亿	流通市值17.49亿	总股本5,720万
成交额3,748万	换手率2.11%	流通股本5,117万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":34.17,"timestamp":1731704400000,"preClose":37.69,"halted":0,"volume":1077786,"hourTrading":{"tag":"盘后","latestPrice":34.17,"preClose":34.17,"latestTime":"19:30 EST","volume":256,"amount":8925.54,"timestamp":1731717042883},"delay":0,"floatShares":51172016,"shares":57196520,"eps":-2.223275,"marketStatus":"已收盘","marketStatusCode":5,"change":-3.52,"latestTime":"11-15 16:00:00 EST","open":37.75,"high":37.76,"low":33.92,"amount":37476117.342539996,"amplitude":0.101884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.223275,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1731920400000},"adr":0,"listingDate":1675400400000,"adjPreClose":37.69,"adrRate":3,"postHourTrading":{"tag":"盘后","latestPrice":34.17,"preClose":34.17,"latestTime":"19:30 EST","volume":256,"amount":8925.54,"timestamp":1731717042883},"volumeRatio":1.677284,"impliedVol":0.8845,"impliedVolPercentile":0.7183},"requestUrl":"/m/hq/s/GPCR/tweets","defaultTab":"tweets","newsList":[{"id":"2483303881","title":"硕迪生物盘中异动 早盘大幅下跌5.33%报35.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483303881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483303881?lang=zh_cn&edition=full","pubTime":"2024-11-15 23:13","pubTimestamp":1731683587,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日23时13分，硕迪生物股票出现异动，股价快速跳水5.33%。截至发稿，该股报35.68美元/股，成交量5.8757万股，换手率0.10%，振幅5.15%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为3.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115231307971a6e07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115231307971a6e07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2483080922","title":"硕迪生物盘中异动 早盘股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483080922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483080922?lang=zh_cn&edition=full","pubTime":"2024-11-12 23:56","pubTimestamp":1731426997,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日23时56分，硕迪生物股票出现异动，股价快速下挫5.14%。截至发稿，该股报36.71美元/股，成交量9.1319万股，换手率0.16%，振幅4.56%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112235637a230e7ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112235637a230e7ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2482732336","title":"硕迪生物盘中异动 股价大涨5.00%报39.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482732336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482732336?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:55","pubTimestamp":1731340521,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日23时55分，硕迪生物股票出现异动，股价快速拉升5.00%。截至发稿，该股报39.92美元/股，成交量14.9095万股，换手率0.26%，振幅5.55%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-26.00百万美元，每股收益-0.53美元，毛利-231736.14美元，市盈率-18.20倍。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111235521971a5c21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111235521971a5c21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2481983778","title":"硕迪生物盘中异动 股价大涨5.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481983778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481983778?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:36","pubTimestamp":1730903792,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时36分，硕迪生物股票出现波动，股价急速上涨5.95%。截至发稿，该股报41.64美元/股，成交量2.449万股，换手率0.04%，振幅2.42%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223632971a4c5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223632971a4c5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2480581909","title":"更新版 1-口服减肥药的疗效和安全性数据 \"极具竞争力\"，维京公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2480581909","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480581909?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:47","pubTimestamp":1730731673,"startTime":"0","endTime":"0","summary":"在早期试验中，接受高剂量100毫克口服药物VK2735治疗的患者在28天后体重平均减轻了8.2%，而安慰剂仅减轻了1.4%。帕里克说，这些数据可能会让该药物 \"在口服肥胖症市场上扮演一个明确的角色\"，并使该公司成为一个 \"可行的参与者\"。正在晚期试验中测试口服减肥药的礼来公司股价在早盘交易中下滑。至少有三位分析师表示，Viking 药物的耐受性继续保持良好，因为没有服用最高剂量 VK2735 的患者退出试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b370e26f2720fe107e8c7591e53ab381","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"更新版 1-口服减肥药的疗效和安全性数据 \"极具竞争力\"，维京公司业绩上升","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0306807586.USD","IE0002141913.USD","IE0002270589.USD","LU0320765059.SGD","LU0456855351.SGD","LU0882574055.USD","GB00BDT5M118.USD","BK4592","IE00B19Z3581.USD","LU0466842654.USD","LU0882574139.USD","LU1894683348.USD","BK4588","LLY","LU0321505868.SGD","LU0203201768.USD","BK4516","LU0238689110.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU0471298694.HKD","SG9999011175.SGD","LU0079474960.USD","GPCR","LU0198837287.USD","LU0689472784.USD","IE0009355771.USD","LU0471298777.SGD","LU0820561909.HKD","LU0256863902.USD","BK4139","LU0289739699.SGD","LU0823416689.USD","LU1883839398.USD","SG9999002224.SGD","LU0354030438.USD","LU1061106388.HKD","SG9999003800.SGD","BK4533","LU1035775433.USD","LU1093756168.USD","LU0106261372.USD","LU0203202063.USD","LU1057294990.SGD","NVO","IE000M9KFDE8.USD","LU0708995401.HKD","LU0225284248.USD"],"gpt_icon":1},{"id":"2479848030","title":"硕迪生物盘中异动 大幅上涨5.01%报39.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479848030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479848030?lang=zh_cn&edition=full","pubTime":"2024-10-31 23:28","pubTimestamp":1730388491,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日23时28分，硕迪生物股票出现波动，股价快速上涨5.01%。截至发稿，该股报39.76美元/股，成交量18.8581万股，换手率0.33%，振幅4.46%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为3.54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103123281198e3fc38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103123281198e3fc38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2478671575","title":"GPCR药物开发商Septerna(SEPN.US)IPO规模上调57% 定价18美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2478671575","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478671575?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:44","pubTimestamp":1729842267,"startTime":"0","endTime":"0","summary":"智通财经获悉，生物技术公司Septerna周四提高了其即将进行的首次公开募股的拟议交易规模。该公司目前计划以每股18美元的价格发行1530万股股票，以筹资2.75亿美元。据悉，Septerna成立于2019年，专注于开发针对整个G蛋白偶联受体类的新型口服小分子药物。该公司目前正在进行一项针对罕见内分泌疾病甲状旁腺功能低下患者的i期试验，预计将于2025年中期获得顶线数据。该公司截至2024年6月30日的12个月收入为100万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GPCR","BK4007","SEPN"],"gpt_icon":0},{"id":"2477355157","title":"硕迪生物盘中异动 下午盘大幅跳水5.08%报37.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477355157","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477355157?lang=zh_cn&edition=full","pubTime":"2024-10-24 01:10","pubTimestamp":1729703422,"startTime":"0","endTime":"0","summary":"北京时间2024年10月24日01时10分，硕迪生物股票出现异动，股价快速下挫5.08%。截至发稿，该股报37.41美元/股，成交量29.9753万股，换手率0.52%，振幅5.25%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-26.00百万美元，每股收益-0.53美元，毛利-231736.14美元，市盈率-17.21倍。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为1.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024011023971a1db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024011023971a1db8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2477558597","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558597","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558597?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4T3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK5011","LU0964806797.USD","BK4533","LU0310800965.SGD","LU1066053197.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU0553294199.USD","AMGN","IE000M9KFDE8.USD","SG9999001176.USD","SG9999013999.USD","BK4550","LU0211328371.USD","LU0823399737.USD","LU0058720904.USD","LU0345777659.USD","LU0868494617.USD","LU0784385840.USD","IE00BJT1NW94.SGD","LU0972486137.USD","BK4139","BK4530","LU0957799991.USD","AZN.UK","IE00BFTCPJ56.SGD","LU0211327993.USD","PFE","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","LU0047473722.EUR","LU1883839398.USD","BK4007","CTLT","GPCR","LU0321505868.SGD","LU0557290698.USD","LU0661504455.SGD","LU1061106388.HKD","LU0289739699.SGD","LU0757432116.USD","LU0738911758.USD","BK4566","VKTX","LU0122379950.USD","03165","IE00B19Z3B42.SGD","LU1066051498.USD","LU0211326755.USD"],"gpt_icon":1},{"id":"2477558594","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558594","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558594?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","AMGN","BK4550","03165","LU0757432116.USD","SG9999001176.USD","IE00BJT1NW94.SGD","LU0957799991.USD","LU0823399737.USD","BK4007","LU0784385840.USD","BK4139","BK4566","LU0047473722.EUR","LU0310800965.SGD","SG9999002224.SGD","BK4530","CTLT","BK5011","IE00BJJMRZ35.SGD","LU0557290698.USD","LU0964806797.USD","LU0122379950.USD","LU0661504455.SGD","LU0972486137.USD","SGXZ57979304.SGD","BK4533","GPCR","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0345777659.USD","LU0211327993.USD","LU0868494617.USD","LU0553294199.USD","LU0882574055.USD","LU1883839398.USD","PFE","IE000M9KFDE8.USD","LU0211326755.USD","LU1061106388.HKD","SG9999013999.USD","LU0738911758.USD","LU0211328371.USD","VKTX","LU1066051498.USD","IE00BFTCPJ56.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2477539245","title":"更新版 3-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477539245","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477539245?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 3-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 6 段增加了首席执行官的评论，第 13 段增加了康泰伦特的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官说，有关部门应该阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU0234572021.USD","LU0949170426.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0972486137.USD","BK5011","LU0128525689.USD","PFE","SG9999002232.USD","LU0963555726.SGD","CTLT","LU0969580561.USD","BK4007","VKTX","BK4530","LU0052756011.USD","LU0211327993.USD","IE00B2B36J28.USD","LU0225284248.USD","LU0310800379.SGD","AZN.UK","LU0321505439.SGD","LU0949170772.SGD","LU0011850046.USD","AMGN","LU0320765992.SGD","LU0557290698.USD","BK4566","LU1061106388.HKD","LU0792757196.USD","BK4568","GPCR","IE000M9KFDE8.USD","LU0345777659.USD","BK4139","LU0114720955.EUR","03165","LU0823416689.USD","LU0170899867.USD","LU0122379950.USD","LU0128525929.USD","LU0708994859.HKD","LU1057294990.SGD","LU0203345920.USD","LU0526926950.USD","LU0211326755.USD","LU0985481810.HKD","IE0002141913.USD"],"gpt_icon":1},{"id":"2477809590","title":"GPCR药物开发商Septerna(SEPN.US)拟IPO筹资1.75亿美元 估值超6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477809590","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477809590?lang=zh_cn&edition=full","pubTime":"2024-10-22 15:59","pubTimestamp":1729583976,"startTime":"0","endTime":"0","summary":"智通财经获悉，生物技术公司Septerna周一宣布了其IPO条款，该公司专注于开发针对整个G蛋白偶联受体类的新型口服小分子药物。这家总部位于加州南旧金山的公司计划以每股15美元至17美元的价格发行1090万股股票，筹资1.75亿美元。按照拟议定价区间的中点计算，Septerna完全稀释后的市值将达到6.26亿美元。Septerna正在开发靶向GPCR的口服小分子药物。Septerna成立于2019年，截至2024年6月30日的12个月收入为100万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GPCR","BK4007","SEPN"],"gpt_icon":0},{"id":"2476486769","title":"消费者团体要求美国联邦贸易委员会阻止诺和诺德控股公司与卡塔伦特公司的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2476486769","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476486769?lang=zh_cn&edition=full","pubTime":"2024-10-18 02:00","pubTimestamp":1729188006,"startTime":"0","endTime":"0","summary":"        *      消费者团体和工会向美国联邦贸易委员会表达竞争担忧        *      交易可能会限制开发 GLP-1 药物的竞争对手的选择        *      对基因疗法生产的影响也引起了关注   Jody Godoy/Maggie Fick    路透纽约10月17日 - 五个美国消费者团体和两个大型工会周四敦促美国联邦贸易委员会阻止诺和诺德公司  的控股股东收购合同药品制造商康泰伦特  ，称该交易威胁到减肥药和尖端基因疗法领域的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1061106388.HKD","LU0225771236.USD","LU1023059063.AUD","LU0109394709.USD","CTLT","GPCR","LU0289739699.SGD","BK4139","IE00BLSP4239.USD","IE0002141913.USD","AMGN","LU0170899867.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0306806265.USD","LU2112291526.USD","LU1983299246.USD","SG9999001176.SGD","LU1057294990.SGD","SG9999011175.SGD","LU0868494617.USD","BK4532","LU1894683348.USD","SG9999013999.USD","BK4581","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0321505868.SGD","BK4534","LU0889565916.HKD","VKTX","LU0321505439.SGD","LU1894683264.USD","SG9999003800.SGD","LU0456855351.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU0225284248.USD","IE0002270589.USD","BK4592","LU1066053197.SGD","SRPT","SG9999001176.USD","IE00BJT1NW94.SGD","LLY","LU1093756168.USD","LU0320765992.SGD","NVO","BK4533"],"gpt_icon":1},{"id":"2476947304","title":"硕迪生物盘中异动 下午盘股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476947304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476947304?lang=zh_cn&edition=full","pubTime":"2024-10-17 01:17","pubTimestamp":1729099039,"startTime":"0","endTime":"0","summary":"北京时间2024年10月17日01时17分，硕迪生物股票出现异动，股价急速上涨5.12%。截至发稿，该股报38.16美元/股，成交量29.0396万股，换手率0.51%，振幅5.58%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017011720ab6a95ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017011720ab6a95ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2475317092","title":"硕迪生物盘中异动 临近收盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475317092","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475317092?lang=zh_cn&edition=full","pubTime":"2024-10-15 03:50","pubTimestamp":1728935446,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日03时50分，硕迪生物股票出现异动，股价急速下跌5.02%。截至发稿，该股报36.40美元/股，成交量74.7968万股，换手率1.31%，振幅6.08%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015035046971a02ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015035046971a02ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR"],"gpt_icon":0},{"id":"2473487338","title":"硕迪生物盘中异动 下午盘股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473487338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473487338?lang=zh_cn&edition=full","pubTime":"2024-10-08 02:28","pubTimestamp":1728325699,"startTime":"0","endTime":"0","summary":"北京时间2024年10月08日02时28分，硕迪生物股票出现波动，股价大幅跳水5.19%。截至发稿，该股报40.76美元/股，成交量23.1595万股，换手率0.40%，振幅6.07%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.09%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100802281998e3ae92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100802281998e3ae92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR"],"gpt_icon":0},{"id":"2472145575","title":"硕迪生物盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472145575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472145575?lang=zh_cn&edition=full","pubTime":"2024-10-03 00:01","pubTimestamp":1727884895,"startTime":"0","endTime":"0","summary":"北京时间2024年10月03日00时01分，硕迪生物股票出现异动，股价急速拉升5.02%。截至发稿，该股报44.31美元/股，成交量29.3117万股，换手率0.51%，振幅5.68%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.87%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410030001359719dfe6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410030001359719dfe6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR"],"gpt_icon":0},{"id":"2471038561","title":"硕迪生物盘中异动 早盘股价大涨5.10%报43.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471038561","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471038561?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:50","pubTimestamp":1727704250,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日21时50分，硕迪生物股票出现波动，股价大幅上涨5.10%。截至发稿，该股报43.88美元/股，成交量9.7583万股，换手率0.17%，振幅4.26%。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.21%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930215050ab67285a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930215050ab67285a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0},{"id":"2470303290","title":"硕迪生物盘中异动 股价大跌5.07%报41.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470303290","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470303290?lang=zh_cn&edition=full","pubTime":"2024-09-26 03:48","pubTimestamp":1727293713,"startTime":"0","endTime":"0","summary":"北京时间2024年09月26日03时48分，硕迪生物股票出现异动，股价急速跳水5.07%。截至发稿，该股报41.79美元/股，成交量89.5355万股，换手率1.57%，振幅7.52%。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.58%。消息层面，截至03时48分，硕迪生物股票正面舆情新闻比例10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926034833a1dc82c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926034833a1dc82c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR"],"gpt_icon":0},{"id":"2469641307","title":"硕迪生物盘中异动 早盘快速上涨5.03%报44.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469641307","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469641307?lang=zh_cn&edition=full","pubTime":"2024-09-24 23:24","pubTimestamp":1727191461,"startTime":"0","endTime":"0","summary":"北京时间2024年09月24日23时24分，硕迪生物股票出现波动，股价急速拉升5.03%。截至发稿，该股报44.48美元/股，成交量55.9504万股，换手率0.98%，振幅4.10%。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.80%。消息层面，截至23时24分，硕迪生物股票正面舆情新闻比例11.11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092423242198e38af5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092423242198e38af5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":0.0383},{"period":"3month","weight":0.0154},{"period":"6month","weight":0.0426},{"period":"1year","weight":-0.22},{"period":"ytd","weight":-0.0753}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"硕迪生物公司于2019年2月在开曼群岛成立，在美国和中国设有运营子公司。该公司是一家临床阶段的全球生物制药公司，旨在开发和提供新型口服疗法，以治疗各种慢性疾病，满足医疗需求。公司的差异化技术平台利用基于结构的药物发现和计算化学专业知识，使公司能够开发口服小分子疗法，用于治疗各种疾病，包括影响代谢、心血管和肺系统的疾病。","exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}